Andrew Alexander, DVM, PhD, MBA, DABT, is Lovelace’s Senior Director of Preclinical Toxicology and is responsible for business development, operations, and scientific rigor across Lovelace’s preclinical research programs. As Senior Director, Alexander works closely with study directors, principal investigators, operations, and leadership teams to optimize study designs, workflows, streamline proposal, quoting, and reporting processes, and support the expansion of new service lines and preclinical research models.
Dr. Alexander brings more than 30 years of experience in veterinary medicine, academic research, and preclinical safety assessment and toxicology, with a career centered on building efficient, scalable preclinical operations that deliver high-quality science on predictable timelines. His background spans exploratory, non-GLP, and GLP toxicology and medical device studies across a wide range of therapeutic modalities, species, and delivery routes.
Prior to joining Lovelace, he held senior leadership roles at Covance (now LabCorp) and Inotiv, overseeing preclinical toxicology, pharmacology, surgical and medical device safety programs. His experience includes study direction, leadership of large multidisciplinary teams, site leadership, full P&L responsibility, capital expansion projects, regulatory inspections, and direct collaboration with sponsors, regulators, and internal scientific staff. He has worked with organizations ranging from government and academic institutions, and early-stage startups to Fortune 500 life science companies.
Dr. Doyle-Eisele is a Senior Scientist and the Senior Director of Laboratory Animal Sciences (Life Sciences) at Lovelace Biomedical Research Institute/Lovelace Biomedical. In this capacity, she oversees the major areas of research in the Applied Sciences Division. Her main research emphasis areas intersect Drug Development from early model evaluation to completion of Investigational New Drug/New Drug Applications and Emergency Use Authorizations. Much of this work is in the CBRNE arena. This is conducted through her expertise in pharmacokinetics, pharmacology, toxicology, and specialized capabilities in pulmonary disease, infectious disease, inflammation, and injury. Her division has developed animal models of inflammation (pulmonary/other), acute distress and nervous system (primarily chemical and toxin injury), disposition (ADME and radionuclide models), toxicology (IND/NDA enabling and exploratory), radiation-induced injury (hematopoietic, gastrointestinal, and dermal), chemical injury, and infectious disease (select agent and non-select agent). Dr. Doyle-Eisele oversees Study Directors and technical staff with expertise in each of these research areas. Dr. Doyle-Eisele received a B.S. in chemistry from the University of South Carolina and an MS & Ph.D. in inhalation toxicology and environmental chemistry from the University of North Carolina. Dr. Doyle-Eisele joined Lovelace in 2007.”